Bristol-Myers Sqibb Co. said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs Opdivo and Yervoy is one many Wall Street analysts believe is promising. Two-year overall survival rates for patients with previously untreated advanced melanoma ...
The post Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial appeared first on ForexTV.
April 04, 2017 at 03:52AM
http://ift.tt/2o3oMmH
from Market Watch
http://ift.tt/2o3oMmH
No comments:
Post a Comment